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Summary In this study we examined the case histories of 163 living and 82 deceased adult Finnish patients
with acute hepatic porphyria. There were 184 patients with acute intermittent porphyria and 61 patients with
variegate porphyria. Among the 124 of the 163 living patients, who were traced 1984-1985, no hepatocellular
carcinoma was found.
Among the 82 deceased patients the cause of death was porphyria in 29 (36%), cardiovascular disease in 23
(29%) and hepatocellular carcinoma in 7 (9%). Of the 7 patients with hepatocellular carcinoma, 6 had acute
intermittent porphyria and one had variegate porphyria.
In acute hepatic porphyria, as compared with the total population, the calculated risk of hepatocellular
carcinoma is increased 61-fold.
The acute hepatic porphyrias are a group of inherited
diseases caused by partial enzyme defects in haem
biosynthesis. The commonest types are acute intermittent
porphyria (AIP) and variegate porphyria (VP). Clinically
these porphyrias are characterised by occasional acute
attacks consisting of abdominal pain and various neuro-
psychiatric symptoms.
The prognosis of patients with acute hepatic porphyria has
improved greatly during recent decades (Mustajoki, 1986;
Kappas et al., 1983). Since the increase in life span, several
reports have shown that acute hepatic porphyria may be
complicated by other diseases such as chronic hypertension
(Beattie & Goldberg, 1975) and chronic renal failure (Yeung
Laiwah et al., 1983). An association between hepatocellular
carcinoma (HCC) and AIP was first suggested by Lithner
and Wetterberg in Sweden (1984).
In this study we investigated the causes of death and the
incidence and relative risk of HCC among adults with acute
hepatic porphyria in Finland.
Patients and methods
A register of Finnish patients with acute hepatic porphyria is
based on the previous population study (Mustajoki &
Koskelo, 1976) and a later systematic search for patients and
relatives. According to the register in 1985 there were 163
(121AIP, 42VP) living subjects with acute hepatic porphyria
and 82 (63AIP, 19VP) patients who had died since 1929. The
mean age for the 163 living patients (62 men, 101 women)
was 45 years (range 20-85) and the mean age at death for
the 82 deceased patients (42 men, 40 women) was 57 years
(range 17-96). Fifty-three of the living (33%) and 48 of the
dead patients (59%) were over the age of 50 at the time of
the study or at the time of death, respectively. Fifty-eight of
the deaths (71%) had occurred before 1970.
The diagnostic criteria for the 163 living subjects are given
elsewhere (Mustajoki, 1976; Mustajoki & Koskelo, 1976). In
40 of the 82 deceased patients the diagnosis was based on
adequate laboratory analyses (Mustajoki & Koskelo, 1976).
Thirty-eight patients, who died before modern laboratory
techniques were available, must have been gene carriers
according to their genealogies and 4 patients, who were first
degree relatives of a verified case of porphyria, had typical
clinical symptoms.
During 1984-1985 a questionnaire on liver diseases was
sent to the 165 porphyric subjects, who were known to be
alive at the beginning of 1985, in order to obtain
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information about any present or past liver disease. Replies
were received from 124 subjects (75%); 25 of the remaining
41 patients could not be traced, 14 patients did not respond
to the questionnaire and 2 died during 1985.
Of the 124 patients, 8 reported either transiently elevated
transaminases (7) or a history of hepatitis (1), but none
reported liver tumours. If a liver disease was suspected more
detailed information was studied in the hospital records.
Causes of death were obtained from hospital records and
from the Central Statistical Office of Finland.
The diagnosis of HCC was based on histological
examination of percutaneous needle biopsies in 4 cases (nos.
2, 3, 4, 5) and an operative specimen in 2 cases (nos. 1, 7)
and a biopsy which was obtained at autopsy in one case (no.
6). The diagnosis was confirmed at autopsy in 2 cases (nos,
2, 5). In each case, re-examination of the histological
preparations by an experienced pathologist confirmed the
diagnosis.
The relative risk of HCC in Finland was calculated from
the age-specific incidence rates of primary liver cancer for
males and females in 1953-1982 given by the Finnish Cancer
Registry. The registry was founded in 1953.
In the registry the diagnosis of primary liver cancer
includes all malignant primary liver tumours: HCC,
intrahepatic cholangiocarcinoma, hepatoblastoma and some
rare liver tumours. Metastases and lymphomas are not
included. During the last two decades the diagnosis of
primary liver cancer has been verified histologically in over
90% of the cases in the registry (Pyrhonen, 1986). About
50% of these cases ofprimary liver cancer have been HCC.
Incidence rates for primary liver cancer were used, because
they are more precise and reliable than the mortality rates in
Finland. Moreover, because of the poor prognosis, most
patients with HCC died within a year of diagnosis.
The relative risk of cardiovascular deaths was calculated
from the age-specific mortality rates for males and females in
1956-1960 and 1971-1985 available from the Central
Statistical Office of Finland.
The person-years of porphyric subjects (163 living, 82
dead) were calculated for the period 1953-1985. All the 163
living subjects were included, because most of them were
followed up to the 1980s. The patients entered the study at
the age of 20, because the children with porphyria are not so
well and confidently diagnosed and HCC is a very rare
disease among them. The data were stratified into 5 year age
groups between the ages of 20 to 84. Persons aged 85 or
more constituted the oldest age group.
The relative risk was calculated by dividing the number of
HCCs observed by the number of HCCs to be expected
among porphyric patients. The number of HCC expected
was calculated by multiplying within each age group the
person-years among our porphyric cohort and the mean
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incidence rate of HCC in the total population during 1953-
1982. The number of HCCs observed may be expected to
follow a Poisson distribution. Ninety-nine per cent
confidence limits for the number of HCCs observed were
derived from Diem and Lentner (1975).
Results
Causes ofdeath
The causes of death among the 82 deceased patients are
given in Table 1. The cause of death was porphyria in 29
(36%), cardiovascular disease in 23 (29%) and HCC in 7
cases (9%). In the 7 patients with HCC the disease was
diagnosed between 1973 and 1985. There were 5 other
malignancies: carcinoma of the pancreas in 2, carcinoma of
the stomach, astrocytoma and mediastinal tumour each in
one. The cause of death was unknown for 5 patients. Of the
other non-malignant diseases, pneumonia was the cause of
death in 5, gastrointestinal bleeding in 2 and chronic renal
failure in 2.
Characteristics ofpatients with HCC
The characteristics of the 7 patients with HCC and acute
hepatic porphyria are given in Table II.
One of these patients (no. 2) had a history of hepatitis at
the age of 20 and a period of alcohol consumption at the
age of 30. None of the patients had other diseases or
exposures to drugs or toxins which would explain the HCC.
Alpha-foeto-protein and hepatitis B surface antigen were
tested in only one patient (no. 4); she was alpha-foetoprotein
positive and hepatitis B surface antigen negative. The mean
survival time after diagnosis was 7 months (range 5-12).
Pathology
The histology of the seven cases was examined on routine
haematoxylin-eosin stained samples. All cases were classified
as HCC. Three were classified as well differentiated (2 of
these showed acinar structures), 3 were less well
differentiated (one represented the giant-cell type) and one
was classified as poorly differentiated (Table II).
Extensive necrosis was recorded in 4 cases, definite
cirrhosis in two cases and moderate to severe inflammation
in 4 cases. In 2 of the needle biopsy samples the amount of
non-neoplastic parenchyma was too scanty for adequate
evaluation of the possible cirrhotic and inflammatory
changes.
Relative risk ofHCC
The incidence of HCC in the Finnish population in 1982 was
3.9: 100,000 for men and 1.8:100,000 for women (Finnish
Cancer Registry). Seven cases of HCC were observed during
the 4637 person-years at risk in 1953-1985 in our cohort of
adult porphyric patients. The resulting incidence of HCC
was 151:100,000 and the relative risk of HCC among
porphyric patients was 60.98 (63.61 for men, 55.25 for
women). Ninety-nine per cent confidence limits were 17.75-
145.25 for both sexes, 13.71-180.03 for men and 2.86-256.18
for women.
If patient no. 2 is excluded, because of a history of
hepatitis and a period of alcohol consumption, the relative
risk is 52.26 for both sexes (50.89 for men, 55.25 for
women). Ninety-nine per cent confidence limits were then
13.39-136.41 for both sexes, 8.55-160.24 for men and 2.86-
256.18 for women.
The relative risk of cardiovascular deaths for the
porphyric patients was 1.79 and so the mortality from
cardiovascular diseases was not significantly different
between porphyrics and the total population. The relative
risk was not calculated for other malignancies or other non-
malignant diseases because of the small number of deaths.
Table I Causes of death in the 82 deceased porphyric patients
AIP VP
Total number
ofpatients men women men women RR
Porphyria 29 10 13 2 4
Cardiovascular diseases 23 11 5 2 5 1.79
Hepatocellular carcinoma 7 4 2 1 0 60.98
Other malignancies 5 3 2 0 0
Other non-malignant diseases 13 5 5 2 1
Cause unknown 5 2 2 1 0
All cases 82 35 29 8 10
AIP=acute intermittent porphyria; VP=variegate porphyria; RR =relative risk.
Table II Demographic data and tumour pathology in the 7 patients with hepatocellular carcinoma
Case Type of Type ofhepatocellular
number Sex Age porphyria carcinoma Necrosis Inflammation Cirrhosis
1. M 82 AIP well differentiated + - -
2. M 55 AIP well differentiated - + + +
+acinar structures
3. M 67 AIP less well differentiated + + + + nd
4. F 60 AIP less well differentiated - + + + +
5. F 57 AIP less well differentiated + nd nd
+giant cell
6. M 75 AIP poorly differentiated + ++ - +
7. M 66 VP well differentiated + + +
+acinar structures
AlP=acute intermittent porphyria; VP=variegate porphyria; + =present; -=absent; nd =not
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Discussion
According to our results, among Finnish adult patients with
acute hepatic porphyria the incidence of HCC is high. This
confirms the results for AIP obtained in Sweden (Lithner &
Wetterberg, 1984; Hardell et al., 1984). Thus it seems clear
that the risk of HCC is markedly increased in AIP. The risk
may be increased in VP, too, but no final conclusions can be
drawn because of the small number ofpatients.
Many factors may cause bias in calculations of the relative
risk of HCC in porphyria. As porphyric patients are usually
closely followed up, liver tumours can be expected to be
recognised more easily among them than among the non-
porphyric population. On the other hand, several other
factors may cause the calculated 61-fold risk to be too low.
All the cases with HCC were diagnosed after 1970 whereas
the majority of the deaths had occurred before that year.
This suggests that formerly some cases of HCC were missed
because of incorrect diagnosis. The HCC expected was
calculated from the statistical data of the Cancer Registry
for all primary liver cancers instead of for HCC only, which
further increases the underestimation of the relative risk in
porphyria. Finally, cases of primary liver cancer may have
occurred among the 39 patients who could not be traced.
HCC has been related to several risk factors, especially to
hepatitis B virus and alcohol (Ohnishi et al., 1982; Popper,
1986). Hepatitis B surface antigen carriers have been
reported to have a 10 to 1000-fold risk of HCC in different
population studies (London, 1981; Cook, 1985), the risk
being lower in low prevalence areas such as Europe
(Trichopoulos et al., 1978). A high intake of alcohol has
been reported to lead to a 4.2-fold risk of HCC (Hardell et
al., 1984).
The probability that HCC in the porphyric patients was
due to hepatitis B is minimal, because in Finland the
prevalence of hepatitis B surface antigen carriers is less than
0.05% among blood donors (information from the Finnish
Red Cross Blood Transfusion Service) and there is no reason
to suppose that porphyric patients are more often infected
with hepatitis B virus than the non-porphyric population.
The alcohol consumption of porphyric patients is probably
low compared with that of the total population because all
porphyric patients are advised to avoid alcohol. Indeed,
according to our questionnaire, most of the patients have
reduced their alcohol consumption. Only one of the
porphyric patients with HCC (no. 2) had a period of alcohol
consumption and hepatitis in youth. Exclusion of this patient
from the material did not significantly alter the calculated
risk figures. Thus, we believe that HCC in acute hepatic
porphyria is associated with the porphyria itself.
Several studies have confirmed the 100 to 200-fold risk of
HCC in porphyria cutanea tarda, which does not belong to
the group of acute hepatic porphyrias (Berman & Braun,
1962; Kordac, 1972; Solis et al., 1982). Porphyria cutanea
tarda is associated with gross liver abnormalities (Cortes et
al., 1980), including cirrhosis in many patients which may be
the morphological basis for HCC in this type of porphyria.
In acute hepatic porphyrias the metabolic defect is
manifested in the liver, too, but only minor hepatic abnor-
malities have been demonstrated in these porphyrias
(Biempica et al., 1974; Ostrowski et al., 1983). It is not
known how these abnormalities relate to the pathogenesis of
HCC in AIP and in VP.
There are several other possible ways in which carcino-
genesis could arise in porphyria. For example, porphyrins
are considered to be carcinogenic in themselves (Bengtsson &
Hardell, 1986). An interesting finding is a recently reported
deletion in chromosome lIp in association with hepatitis B
and HCC (Rogler et al., 1985), because the gene for AIP is
situated in the long arm of the same chromosome (Meisler et
al., 1980). Whether modern gene technology will elucidate
the mechanism of carcinogenesis in porphyrias remains to be
seen.
The prognosis of young patients with porphyria has
greatly improved during recent decades (Mustajoki, 1986;
Kappas et al., 1983). Now that patients with porphyria live
longer, associated diseases may become a problem. One of
them is hepatocellular carcinoma which must be taken into
consideration during follow-up of elderly patients with acute
hepatic porphyria.
We are grateful to Professor Lauri Saxen, for examining the
histological samples and to Dr S. Koskinen, for advice on statistics.
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